Immuneering Corp (IMRX NASDAQ) stock market data APIs
$4.436
-0.17(-3.8%)
as of July 11, 2025
Try our APIs with
free plan!
Immuneering Corp Financial Data Overview
Price chart is built with
Anychart
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Prev. Close
4.436
Open
4.2636
High
4.5475
Low
4.1082
52 wk Range
1-4.6
Market Cap
159 M
Shares Outstanding
35 986 K
Revenue
455
EPS
-0.44
Beta
0.002
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Immuneering Corp data using free add-ons & libraries
Get Immuneering Corp Fundamental Data
Immuneering Corp Fundamental data includes:
- Net Revenue: 455
- EBITDA: -63 850 176
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: -0.49
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Immuneering Corp News
New
Immuneering rises on U.S. patent grant for atebimetinib
[Scientists working in the laboratory] sanjeri/E+ via Getty Images * Shares of Immuneering (NASDAQ:IMRX [https://seekingalpha.com/symbol/IMRX]) rose after the company said it has received a patent ...
Immuneering (IMRX) chief people officer Neufeld buys $2498 in stock
Immuneering Corp (NASDAQ:IMRX) Chief People Officer Leah R. Neufeld reported purchasing 700 shares of Class A Common Stock on July 2, 2025, according to a Form 4 filing with the Securities and Exchan...
Jefferies raises Immuneering price target to $3.50 from $1.50 on cancer data
Investing.com - Jefferies raised its price target on Immuneering Corporation (NASDAQ:IMRX) to $3.50 from $1.50 on Wednesday, while maintaining a Hold rating on the stock. For comprehensive analysis ...
Monday 6/23 Insider Buying Report: IMRX, DLTR
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their har...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
